Who
Mark Corrigan
Director
Company insider
Files Form 4 as: Director, Wave Life Sciences; Director, Trevena; Director, Nabriva Therapeutics; Director, Novelion Therapeutics; Director, Nabriva Therapeutics; Director, CoLucid Pharmaceuticals; President & CEO, EPIRUS Biopharmaceuticals; Director, Cubist Pharmaceuticals.
In numbers
- Trades disclosed
- 200
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $11.0M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 16 Mar 2006
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —10,700 at $0.00 | filing |
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 8 Dec 2025filed 10 Dec 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $126K9,600 at $13.09 | filing |
| 8 Dec 2025filed 10 Dec 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Sold | $92K6,515 at $14.07 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,200 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —12,700 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,460 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —32,230 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | Trevenaoption or derivative | SEC FORM 4 Code A | —13,700 at $0.00 | filing |
| 7 Aug 2023filed 9 Aug 2023 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | Trevenaoption or derivative | SEC FORM 4 Code A | —34,250 at $0.00 | filing |
| 15 Aug 2022filed 17 Aug 2022 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 2 Aug 2022filed 4 Aug 2022 | Nabriva Therapeutics | SEC FORM 4 Sold | $1,95610,297 at $0.19 | filing |
| 16 Aug 2021filed 18 Aug 2021 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 28 Jul 2021filed 30 Jul 2021 | Nabriva Therapeutics | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 28 Jul 2021filed 30 Jul 2021 | Nabriva Therapeuticsoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 2 Jun 2021filed 4 Jun 2021 | Nabriva Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 18 Aug 2020filed 20 Aug 2020 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 4 Sep 2019filed 6 Sep 2019 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 31 Jul 2019filed 1 Aug 2019 | Nabriva Therapeuticsoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026WVE · manilatimes.net · 20 Oct 2026Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026WVE · manilatimes.net · 19 Oct 2026WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonWVE · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Mark Corrigan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.